We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

13 hedge funds and large institutions have $389K invested in Scinai Immunotherapeutics in 2022 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.04% more ownership

Funds ownership: 1.75% → 1.79% (+0.04%)

24% less funds holding

Funds holding: 17 → 13 (-4)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

29% less capital invested

Capital invested by funds: $544K → $389K (-$155K)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
13
Holders Change
-4
Holders Change %
-23.53%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$155K
2
Renaissance Technologies
Renaissance Technologies
New York
+$24.7K
3
TPWA
TRUE Private Wealth Advisors
Oregon
+$8.23K
4
APC
Aspire Private Capital
North Carolina
+$1.37K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$61.8K
2
TSS
Two Sigma Securities
New York
-$38K
3
Millennium Management
Millennium Management
New York
-$34K
4
Citadel Advisors
Citadel Advisors
Florida
-$24.7K
5
Morgan Stanley
Morgan Stanley
New York
-$20.6K

SCNI Hedge Fund Activity: Q2 2022 in Review

13 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2022, worth a combined $389K — down 29% from $544K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of SCNI and 1 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Envestnet Asset Management, adding an estimated $155K. The largest seller was Susquehanna International Group, cutting an estimated $61.8K.

  • 13 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2022, down from 17 in Q1 2022.
  • Funds reported $389K of Scinai Immunotherapeutics stock for Q2 2022, down 29% quarter-over-quarter.
  • 1 fund opened new Scinai Immunotherapeutics positions in Q2 2022 and 5 closed out, a net change of -4 holders.
  • The largest Scinai Immunotherapeutics buyer in Q2 2022 was Envestnet Asset Management, an estimated $155K added.
  • The largest Scinai Immunotherapeutics seller in Q2 2022 was Susquehanna International Group, an estimated $61.8K sold.

Based on aggregated 13F filings for Q2 2022.